NCT01119794 - Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Lymphoma, Non-Hodgkins

Interventions

DRUG

Ofatumumab and Bortezomib

Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression

Trial Locations (3)

Unknown

Dartmouth-Hitchcock Medical Center, Hanover

02903

Rhode Island Hospital, Providence

02906

Miriam Hospital, Providence